GlassScriptPhysician profile
David G Moore
NPI 1538257969
$642.01
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $86.77 · 2021: $18.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $158.02 | 2019-2020 | |
| Abbvie INC. | $142.51 | 2019-2020 | |
| Pfizer INC. | $94.31 | 2019-2020 | |
| Astellas Pharma US INC | $47.97 | 2019 | |
| Therapeuticsmd, INC. | $46.38 | 2019-2020 | |
| Boston Scientific Corporation | $43.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.21 | 2019 | |
| Roche Diagnostics Corporation | $24.24 | 2019 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Acessa Health INC. | $13.83 | 2019 | |
| Lupin INC. | $12.96 | 2020 | |
| Merck Sharp & Dohme LLC | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.